Leiden-based Meatable has acquired Uncommon Bio’s technology to expand its capabilities in developing cultivated meat.
Contentlockr
Leiden-based Meatable, a Dutch startup specialising in cultivated meat technology, has acquired Uncommon Bio’s cultivated meat platform, including technology, intellectual property assets, cell lines, and staff.
The acquisition strengthens Meatable’s capabilities in cultivated meat by bringing together its technology, product pipeline, and expertise.
Cell technologies to transform global food production
Founded in 2017, Uncommon Bio first worked on making meat from cells and then developed new ways to deliver RNA into cells. RNA (Ribonucleic Acid) is a molecule that carries instructions from DNA to help cells make proteins.
Using this technology, the company spun out a new business focused on medicine, specifically designing treatments that can target multiple pathways in cells at once. Their delivery system uses polysaccharides to program cells safely and efficiently.
The company is beginning with treatments for serious lung diseases, like idiopathic pulmonary fibrosis, and has backing from industry investors such as BioNTech, Sam Altman, Balderton, Lowercarbon, and Redalpine.
Speaking on the development, Benjamina Bollag, CEO of Uncommon Bio, says, “I’m incredibly proud of what we’ve built at Uncommon Bio, a legacy of innovation and bold thinking in cultivated meat. After deciding to focus on therapeutics, we wanted to find the best home for our technology, and it’s exciting to see Meatable carry our work forward and apply it at scale.”
“I look forward to continuing our collaboration and watch their continued success and global impact in the years ahead.”
Aim of the acquisition
By integrating Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies with its patented opti-ox system, Meatable now operates a multi-platform cultivated meat technology.
This combination allows the company to advance product development, address regulatory requirements in different regions, and respond to varying consumer and cultural needs.
Jeff Tripician, CEO of Meatable, says, “This acquisition is more than a strategic step – it sets a new standard for cultivated meat production. By combining two highly complementary platforms, Meatable is now equipped to reliably deliver high-quality cultivated meat at a global scale.”
“This enables us to support the meat industry with a stable, secure, and future-proof supply of species like pork, beef, lamb, and poultry, ensuring business continuity and resilience in the face of increasingly uncertain times.”
Meatable’s acquisition of Uncommon Bio includes technology, patents, and proprietary assets. The deal adds methods for developing chicken, lamb, and other breeds, along with a regulatory dossier to support approval processes in multiple regions.
Meatable is also building partnerships across the meat supply chain to supplement traditional livestock production. The company plans to scale production to meet global demand for meat while avoiding risks linked to animal disease.
Aris de Rijke, CTO at Meatable, says, “The value of the IP is strengthened by the caliber of investors who have supported Uncommon’s mission from the start. We’re proud to carry forward technology that has earned the trust of such respected backers, like Apollo Projects and Lower Carbon Capital, further fueling our path toward success at scale.”
With additional intellectual property, cell lines, and applications, Meatable now operates a multi-platform cultivated meat strategy. The company aims to produce cultivated meat at scale for global consumption.
Brief about Meatable
Meatable is developing cultivated meat technology that works alongside existing meat industry supply chains. The company positions itself as a partner to producers by offering scientific and technological methods for producing meat without the use of animals.
According to Meatable, its process is significantly faster than conventional production methods and is intended to support global demand for protein.
